First & Only FDA approved DES for Diabetes now available in Chandigarh
Diabetes is a growing lifestyle disease in India; currently, over 370 million people suffer from diabetes across the globe, which is expected to exceed 550 million by 2030. The number of diabetic patients is expected to increase to almost 80 million in 2030 in India. Seven million people in India develop diabetes annually .
Unfortunately, in India diabetes and heart disease often go hand in hand. Therefore, diabetic patients must get screened for heart disorders. Many diabetic patients may not exhibit symptoms such as chest pain or shortness of breath; however may suffer coronary artery disease (CAD) or are at high risk for cardiovascular events, including myocardial infarction (MI). Myocardial infarction is the scientific name for a heart attack.
Percutaneous Coronary Intervention (PCI) with stenting is becoming a more preferred option by doctors to treat Diabetic patients suffering from coronary artery disease in India.
With the introduction of next generation stent in India, diabetic patients have a new hope. The Resolute Integrity (RI) is the first and the only stent approved by the US FDA for Diabetic patients. Patients with diabetes mellitus (DM) are prone to a diffuse and rapidly progressive form of atherosclerosis, which increases their likelihood of requiring revascularization.
Resolute Integrity DES, the innovative technology used, combines the powerful clinical advantages of Resolute DES with the groundbreaking continuous sinusoid technology (CST) that encompasses one continuous, single strand of wire, making each stent comparable to a flexible spring. The result is a revolutionary new DES that provides superior deliverability and powerful clinical performance, making it even easier to address the needs of complex cases especially occurring in Diabetic patients.
Dr. R K Jaswal, Director, Cardiologist, Fortis Hospital, Mohali says “Resolute Integrity shows considerable improvement in terms of deliverability and ease of use when compared to its peers. The clinical results are also very satisfactory with RI. The depth and quality of clinical data in diabetic patients is especially commendable. The TLR (Target Lesion Revascularization) rates are much better when compared to conventional CABG (Coronary Artery Bypass Graft). RI is the only FDA approved stent for diabetics and my first choice for such complex category of patients.”